Single ascending oral dose pharmacokinetics and pharmacodynamics study of EV-077: The specific inhibitor of prostanoid- and isoprostane-induced cellular activation

European Journal of Clinical Pharmacology

Volumn 69, Issue 3, 2013, Pages 459-465

  Richardson, A ^a   Sakariassen, K S ^b   Meyer, J P ^c   Alberts, P ^c   Sorensen, A S ^c  

^a AR Pharma Projects   (United Kingdom)

^b KellSa sas   (Italy)

^c Evolva S A   (Switzerland)

Author keywords

EV 077; Pharmacokinetics; Platelet aggregation; Single dose

Indexed keywords

EV 077; PLACEBO; THROMBOXANE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; HEMATOMA; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE AGGREGATION INHIBITION; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BLEEDING TIME; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; HALF-LIFE; HUMANS; LINEAR MODELS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, THROMBOXANE; THROMBOXANE-A SYNTHASE; YOUNG ADULT;

EID: 84877128891     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1348-9     Document Type: Article

References (14)

1. Fontana P, Alberts P, Sakariassen KS, Bounameaux H, Meyer J-P, Sorensen SA (2011) The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin. J Thromb Haemost 9:2109-2111
2. Sakariassen KS, Alberts P, Fontana P, Mann J, Bounameaux H, Sorensen AS (2009) Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. Future Cardiol 5:479-493
3. Moncada S, Vane JR (1978) Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 30:293-331
4. Sakariassen KS, Femia E, Rothlin RP, Podda G-M, Razzari C, Pugliano M-T, Daray FM, Errasti EA, Armesto AR, Nowak W, Alberts P, Hermosilla R, Meyer J-P, Cattaneo M, Sorensen SA (2011) EV-077-3201-2TBS, a TP antagonist and TS inhibitor, reduces platelet aggregation in whole blood of type 2 diabetics with coronary artery disease on chronic aspirin therapy. J Thromb Haemost 9(Suppl. 2):Abstract O-MO-023
5. Sakariassen KS, Muggli R, Baumgartner HR (1989) Measurements of platelet interaction with components of the vessel wall in flowing blood. Methods Enzymol 169:37-70
6. Cattaneo M, Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD (2009) Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost 7:1029
7. Sonksen JR, Kong KL, Holder R (1999) Magnitude and time course of impaired primary haemostasis after stopping chronic low and medium dose aspirin in healthy volunteers. Br J Anaesth 82:360-365
8. Wilhite DB, Comerota AJ, Schmieder FA, Throm RC, Gaughan JP, Rao AK (2003) Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 38:710-713
9. Cohen RA, Feletou M, Vanhoutte PM, Verbeuren TJ (2010) TP receptors and oxidative stress hand in hand from endothelial dysfunction to atherosclerosis. Adv Pharmacol 60:85-106
10. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685-1695
11. Pratico D (2008) Prostanoid and isoprostanoid pathways in atherogenesis. Atherosclerosis 201:8-16
12. Ross R (1999) Atherosclerosis - an inflammatory disease. N Engl J Med 340:115-126
13. Santilli F, Mucci L, Davi G (2011) TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus. Intern Emerg Med 6:203-212
14. Vezza R, Mezzasoma AM, Venditti G, Gresele P (2002) Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets. Thromb Haemost 87:114-121